NMNH Supplement Shows Promise for Healthy Aging in 80-Person Clinical Trial
New study evaluates reduced nicotinamide mononucleotide for anti-aging benefits, measuring biological age and physical performance.
Summary
Researchers completed a clinical trial testing NMNH, a reduced form of nicotinamide mononucleotide, as an anti-aging supplement in 80 healthy adults. The study aimed to evaluate safety, tolerability, and potential benefits for healthy aging including effects on physical performance, biological age, and quality of life. NMNH is related to NAD+ metabolism, a cellular process that declines with age and affects energy production. The trial compared NMNH supplementation against placebo over several months to assess its therapeutic potential for anti-aging interventions and guide future clinical applications.
Detailed Summary
A recently completed clinical trial investigated NMNH (reduced nicotinamide mononucleotide) as a potential anti-aging supplement, marking an important step in longevity research. The study aimed to comprehensively evaluate NMNH's safety, tolerability, and efficacy for healthy aging applications.
The randomized, placebo-controlled trial enrolled 80 healthy adult participants over a six-month period from July 2024 to January 2025. Participants received either NMNH supplementation or placebo while researchers monitored multiple health parameters.
Researchers measured pharmacokinetics to understand how the body processes NMNH, along with assessments of physical performance, biological age markers, and overall quality of life. These comprehensive measurements were designed to capture NMNH's potential effects across multiple aspects of aging and health optimization.
The trial has reached completion, though specific results have not yet been published. NMNH represents a modified form of nicotinamide mononucleotide, which is involved in NAD+ metabolism - a crucial cellular process that declines with age and affects energy production, DNA repair, and cellular health.
These findings will contribute to our understanding of NAD+ precursor supplementation for longevity applications. The study's comprehensive approach, measuring both biological markers and functional outcomes, could provide valuable insights for individuals interested in evidence-based anti-aging interventions and guide future research directions in this rapidly evolving field.
Key Findings
- 80-person randomized trial of NMNH supplement completed for healthy aging research
- Study measured biological age, physical performance, and quality of life markers
- Six-month trial evaluated safety and tolerability of reduced nicotinamide mononucleotide
- Research focused on NAD+ metabolism pathway for anti-aging applications
Methodology
Randomized, placebo-controlled trial with 80 healthy adult participants over approximately 6 months. The study compared NMNH supplementation against placebo with comprehensive safety and efficacy monitoring.
Study Limitations
Results have not yet been published, limiting assessment of actual efficacy and safety outcomes. The study focused on healthy adults, so findings may not apply to older populations or those with age-related conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.